71 related articles for article (PubMed ID: 30909944)
1. Identifying the Antiproliferative Effect of
Liu C; Li H; Wang K; Zhuang J; Chu F; Gao C; Liu L; Feng F; Zhou C; Zhang W; Sun C
Front Oncol; 2019; 9():368. PubMed ID: 31157164
[No Abstract] [Full Text] [Related]
2. A review of the biological activity and pharmacology of cryptotanshinone, an important active constituent in Danshen.
Li H; Gao C; Liu C; Liu L; Zhuang J; Yang J; Zhou C; Feng F; Sun C; Wu J
Biomed Pharmacother; 2021 May; 137():111332. PubMed ID: 33548911
[TBL] [Abstract][Full Text] [Related]
3. Cardiotoxicity of doxorubicin-based cancer treatment: What is the protective cognition that phytochemicals provide us?
Liu C; Ma X; Zhuang J; Liu L; Sun C
Pharmacol Res; 2020 Oct; 160():105062. PubMed ID: 32652197
[TBL] [Abstract][Full Text] [Related]
4. The Modulatory Properties of
Liu C; Wang K; Zhuang J; Gao C; Li H; Liu L; Feng F; Zhou C; Yao K; Deng L; Wang L; Li J; Sun C
Front Pharmacol; 2019; 10():1171. PubMed ID: 31680955
[No Abstract] [Full Text] [Related]
5. Integrated analysis of co-expression and ceRNA network identifies five lncRNAs as prognostic markers for breast cancer.
Yao Y; Zhang T; Qi L; Zhou C; Wei J; Feng F; Liu R; Sun C
J Cell Mol Med; 2019 Dec; 23(12):8410-8419. PubMed ID: 31613058
[TBL] [Abstract][Full Text] [Related]
6. Integrative transcriptome data mining for identification of core lncRNAs in breast cancer.
Zhang X; Zhuang J; Liu L; He Z; Liu C; Ma X; Li J; Ding X; Sun C
PeerJ; 2019; 7():e7821. PubMed ID: 31608179
[TBL] [Abstract][Full Text] [Related]
7. A Thia-Analogous Indirubin
Wendt F; Wittig F; Rupprecht A; Ramer R; Langer P; Emmert S; Frank M; Hinz B
Cells; 2023 Oct; 12(19):. PubMed ID: 37830623
[TBL] [Abstract][Full Text] [Related]
8. Assessing the Anti-inflammatory Effects of Bacopa-Derived Bioactive Compounds Using Network Pharmacology and
Jeyasri R; Muthuramalingam P; Adarshan S; Shin H; Ramesh M
ACS Omega; 2022 Nov; 7(44):40344-40354. PubMed ID: 36385888
[No Abstract] [Full Text] [Related]
9. Cryptotanshinone Is a Intervention for ER-Positive Breast Cancer: An Integrated Approach to the Study of Natural Product Intervention Mechanisms.
Li H; Gao C; Liang Q; Liu C; Liu L; Zhuang J; Yang J; Zhou C; Feng F; Sun C
Front Pharmacol; 2020; 11():592109. PubMed ID: 33505309
[No Abstract] [Full Text] [Related]
10. [MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia].
Tsubaki M
Yakugaku Zasshi; 2018; 138(12):1461-1466. PubMed ID: 30504658
[TBL] [Abstract][Full Text] [Related]
11. Imatinib: a review of its use in chronic myeloid leukaemia.
Moen MD; McKeage K; Plosker GL; Siddiqui MA
Drugs; 2007; 67(2):299-320. PubMed ID: 17284091
[TBL] [Abstract][Full Text] [Related]
12. Deciphering the mechanism of Indirubin and its derivatives in the inhibition of Imatinib resistance using a "drug target prediction-gene microarray analysis-protein network construction" strategy.
Li H; Liu L; Zhuang J; Liu C; Zhou C; Yang J; Gao C; Liu G; Sun C
BMC Complement Altern Med; 2019 Mar; 19(1):75. PubMed ID: 30909944
[TBL] [Abstract][Full Text] [Related]
13. Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
Hekmatshoar Y; Ozkan T; Altinok Gunes B; Bozkurt S; Karadag A; Karabay AZ; Sunguroglu A
Cell Mol Biol (Noisy-le-grand); 2018 May; 64(6):23-30. PubMed ID: 29808796
[TBL] [Abstract][Full Text] [Related]
14. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
[TBL] [Abstract][Full Text] [Related]
15. miR-101 sensitizes K562 cell line to imatinib through Jak2 downregulation and inhibition of NF-κB target genes.
Farhadi E; Zaker F; Safa M; Rezvani MR
Tumour Biol; 2016 Oct; 37(10):14117-14128. PubMed ID: 27517565
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
